We have located links that may give you full text access.
Long-term outcome of liver transplantation for autoimmune hepatitis: a French nationwide study over 30 years.
Liver International : Official Journal of the International Association for the Study of the Liver 2023 Februrary 25
BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a rare indication for liver transplantation (LT). The aims of this study were to evaluate long-term survival after LT for AIH and prognostic factors, especially the impact of recurrent AIH (rAIH).
METHODS: A multicenter retrospective nationwide study including all patients aged ≥16 transplanted for AIH in France was conducted. Early deaths and retransplantations (≤ 6 months) were excluded.
RESULTS: The study population consisted in 301 patients transplanted from 1987 to 2018. Median age at LT was 43 years (IQR, 29.4-53.8). Median follow-up was 87.0 months (IQR, 43.5-168.0). Seventy-four patients (24.6%) developed rAIH. Graft survival was 91%, 79%, 65% at 1, 10, and 20 years, respectively. Patient survival was 94%, 84% and 74% at 1, 10 and 20 years, respectively. From multivariate Cox regression, factors significantly associated with poorer patient survival were patient age ≥ 58 years (HR=2.9; 95% CI, 1.4-6.2; p=0.005) and occurrence of an infectious episode within the 1st year after LT (HR=2.5; 95% CI, 1.2-5.1; p=0.018). Risk factors for impaired graft survival were: occurrence of rAIH (HR=2.7; 95% CI, 1.5-5.0; p=0.001), chronic rejection (HR=2.9; 95% CI, 1.4-6.1; p=0.005), biliary (HR=2.0; 95% CI, 1.2-3.4; p=0.009), vascular (HR=1.8; 95% CI, 1.0-3.1; p=0.044) and early septic (HR=2.1; 95% CI, 1.2-3.5; p=0.006) complications.
CONCLUSION: Our results confirm that survival after LT for AIH is excellent. Disease recurrence and chronic rejection reduce graft survival. The occurrence of an infectious complication during the first year post-LT identifies at-risk patients for graft loss and death.
METHODS: A multicenter retrospective nationwide study including all patients aged ≥16 transplanted for AIH in France was conducted. Early deaths and retransplantations (≤ 6 months) were excluded.
RESULTS: The study population consisted in 301 patients transplanted from 1987 to 2018. Median age at LT was 43 years (IQR, 29.4-53.8). Median follow-up was 87.0 months (IQR, 43.5-168.0). Seventy-four patients (24.6%) developed rAIH. Graft survival was 91%, 79%, 65% at 1, 10, and 20 years, respectively. Patient survival was 94%, 84% and 74% at 1, 10 and 20 years, respectively. From multivariate Cox regression, factors significantly associated with poorer patient survival were patient age ≥ 58 years (HR=2.9; 95% CI, 1.4-6.2; p=0.005) and occurrence of an infectious episode within the 1st year after LT (HR=2.5; 95% CI, 1.2-5.1; p=0.018). Risk factors for impaired graft survival were: occurrence of rAIH (HR=2.7; 95% CI, 1.5-5.0; p=0.001), chronic rejection (HR=2.9; 95% CI, 1.4-6.1; p=0.005), biliary (HR=2.0; 95% CI, 1.2-3.4; p=0.009), vascular (HR=1.8; 95% CI, 1.0-3.1; p=0.044) and early septic (HR=2.1; 95% CI, 1.2-3.5; p=0.006) complications.
CONCLUSION: Our results confirm that survival after LT for AIH is excellent. Disease recurrence and chronic rejection reduce graft survival. The occurrence of an infectious complication during the first year post-LT identifies at-risk patients for graft loss and death.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app